New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AstraZeneca PLC

AZN

Healthcare Drug Manufacturers General

AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.

Revenue
+6.70%
EPS
+23.5%
Free cash flow
+1.99%
Total debt
+1.75%

Quarter to September 2026, against a year earlier

175.75 0.30 +0.17%
Market cap
$272.1B
P/E
24.6×
Fwd P/E FY26e
24.2×
Dividend yield
1.83%
F-score
9/9
ROIC
12.3%
Net debt / EBITDA
1.1×
Payout ratio
0.5×

Latest quarter Q3 FY2026 · quarter to September 2026

Revenue grew 6.70% on a year earlier, against 6.40% the quarter before.

Q3 FY2026 and the seven quarters before it
Quarter Revenue, $m Growth, % Op. margin, % EPS, $
Q3 FY26 16,209 6.7 27.1 2.00
Q2 FY26 15,384 6.4 20.6 1.61
Q1 FY26 15,288 12.5 27.8 1.97
Q4 FY25 15,503 4.1 19.2 1.48
Q3 FY25 15,191 12.0 23.6 1.62
Q2 FY25 14,457 11.7 24.3 1.58
Q1 FY25 13,588 7.2 27.0 1.86
Q4 FY24 14,891 23.8 13.7 0.96

Against the consensus: revenue beat by 0.71% ($16.2B v $16.1B); adjusted EPS beat by $0.19 ($2.79 v $2.60).

Growth is on the same quarter a year earlier, and EPS is diluted. Negative figures in brackets.

Reports Feb 9, 2027 · Dec 2026 · consensus EPS $2.23

All quarters →

Capital & Financial Ratios $m

Size
Market Cap 272,050
Revenue ttm 62,384
Net income ttm 13,300
Free cash flow ttm 6,333
Net debt Q 23,228
Valuation
P/E 24.6
Forward P/E FY26e 24.2
Price / sales 4.4
Forward P/S FY26e Powerpack
Price / FCF 43.0
Price / book 5.3
Financial health
Current ratio Q 1.0
Debt / equity Q 0.6
Interest coverage Q 9.2
Growth
Revenue growth FY26e +7.9%
EPS growth FY26e +12.1%
EPS growth FY27e +10.8%
EPS growth, 5 yrs e +11.2%
Insiders
Net sold 12m 2
Sells 12m 1
Buys 12m 1
Owned by insiders 3.3%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY26e the fiscal year ending in 2026; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales 9.05% 17.15% 9.82%
Cash Flow 15.93% 24.88% 14.11%
Earnings 13.73% 26.19% 45.96%
Book Value 10.16% 25.52% 9.55%

Valuation

P/E against its own 10 years 11.37%
10-year low 10-year high
P/S against its own 10 years 41.65%
10-year low 10-year high
P/B against its own 10 years 28.68%
10-year low 10-year high
EV/Sales against its own 10 years 34.02%
10-year low 10-year high
EV/FCF against its own 10 years 85.13%
10-year low 10-year high

Dividends raised 3 years running

Yield
1.83%
Annual rate
3.21
Payout ratio
45.4%
Growth, 2018–26
+1.72%/yr
  1. 2.80 ’18
  2. 2.80 ’19 +0
  3. 2.80 ’20 +0
  4. 2.80 ’21 +0
  5. 2.90 ’22 +4
  6. 2.90 ’23 +0
  7. 2.97 ’24 +2
  8. 3.13 ’25 +5
  9. 3.21 ’26 +3
paid change on the year, % Powerpack

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 23,002 22,465 22,090 24,384 26,617 37,417 44,351 45,811 54,073 58,739 62,384 +11.0% 63,376 67,393 71,464 +6.8%
Gross margin, % 82.06 80.78 77.66 79.82 80.09 66.76 72.06 81.95 81.12 81.90 81.94 (0.2) pt
EBT 3,552 2,227 1,993 1,548 3,916 (265) 2,501 6,899 8,691 12,402 13,300 +14.9%
EBT margin, % 15.44 9.91 9.02 6.35 14.71 (0.71) 5.64 15.06 16.07 21.11 21.32 +5.7 pt
Net income 3,552 2,227 1,993 1,548 3,916 (265) 2,501 6,899 8,691 12,402 13,300 +14.9%
Per share, $
Per share, $ Revenue 18.18 17.74 17.43 18.74 20.29 26.39 28.65 29.57 34.89 37.90 40.22 +8.5%
Earnings 2.76 2.38 1.70 1.02 2.44 0.08 2.12 3.84 4.54 6.60 7.12 +10.2%
Cash flow 3.28 2.83 2.07 2.28 3.66 4.21 6.34 6.68 7.65 9.40 8.53 +12.4%
Capex (0.64) (0.13) 0.77 (0.27) (1.18) (1.13) (1.19) (2.17) (2.84) (3.71) (4.45) +21.7%
Free cash flow 2.64 2.70 2.84 2.02 2.48 3.08 5.15 4.51 4.81 5.69 4.08 +8.9%
Book value 13.18 13.15 11.08 11.22 11.92 27.71 23.94 25.28 26.37 31.43 33.41 +10.1%
Shares, m 1,265 1,266 1,267 1,301 1,312 1,418 1,548 1,549 1,550 1,550 1,550 +2.3%
Valuation, ×
Valuation, × P/E 19.94 28.82 44.68 95.28 41.06 386.17 63.76 34.41 28.59 26.58 24.64 76.9
P/S 3.05 3.87 4.36 5.39 4.98 4.39 4.76 4.49 3.73 4.63 4.36 4.4
P/B 4.21 5.22 6.85 9.00 8.47 4.18 5.70 5.25 4.93 5.58 5.25 5.9
EV/Sales 3.52 4.45 4.95 5.85 5.41 5.01 5.25 4.96 4.16 5.00 4.73 4.9
EV/FCF 24.25 29.28 30.42 54.42 44.33 43.00 29.25 32.49 30.16 33.32 46.64 35.1
Cash, $m
Cash, $m Operating cash flow 4,145 3,578 2,618 2,969 4,799 5,963 9,808 10,345 11,861 14,575 13,232 +15.0%
Capex (805) (161) 979 (347) (1,549) (1,600) (1,842) (3,355) (4,408) (5,756) (6,899) +24.4%
Free cash flow 3,340 3,417 3,597 2,622 3,250 4,363 7,966 6,990 7,453 8,819 6,333 +11.4%
Balance, $m
Balance, $m Working capital (1,994) (3,233) (701) (2,554) (763) 3,650 (3,700) (5,488) (2,039) (1,894) 181 n/m
Net debt 10,879 13,225 13,175 11,298 11,565 23,313 21,787 21,416 23,135 21,988 23,228 +8.1%
Shareholders’ equity 16,669 16,642 14,044 14,596 15,638 39,287 37,058 39,166 40,871 48,719 51,814 +12.7%
Returns, %
Returns, % ROA 5.71 4.77 3.48 2.19 4.99 0.13 3.26 6.03 6.86 9.38 9.41 +3.7 pt
ROIC 11.12 7.69 7.78 7.06 11.86 1.05 3.99 8.45 9.77 12.15 12.31 +1.0 pt
ROE 19.89 18.02 14.05 9.32 21.14 0.41 8.61 15.63 17.58 22.83 22.56 +2.9 pt
People
People Employees 59,700 61,100 64,400 70,600 76,100 83,100 83,500 89,900 94,300 96,100 — +5.4%
Revenue/emp, $m 0.39 0.37 0.34 0.35 0.35 0.45 0.53 0.51 0.57 0.61 — +5.3%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026

AstraZeneca PLC vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ABBV AbbVie Inc. $501.2B 48.8× 37.6× FY26e +10.32% (above 0%: growing) +2,270.00% (above 0%: growing) +9.97% (above 0%: growing) 75.38% 36.01% Compare
MRK Merck & Co., Inc. $328.6B 137× 105× FY26e +4.68% (above 0%: growing) −12.07% (below 0%: shrinking) −19.27% (below 0%: shrinking) 72.95% 31.90% Compare
NVS Novartis AG $277.7B 28.8× 24.0× FY26e +4.67% (above 0%: growing) −68.81% (below 0%: shrinking) −17.81% (below 0%: shrinking) 75.99% 12.26% Compare
AZN AstraZeneca PLC $272.1B 24.6× 24.2× FY26e +6.70% (above 0%: growing) +23.46% (above 0%: growing) +1.99% (above 0%: growing) 81.82% 27.07%
AMGN Amgen Inc. $237.4B 25.2× 24.0× FY26e +8.45% (above 0%: growing) +19.39% (above 0%: growing) −13.98% (below 0%: shrinking) 73.10% 35.79% Compare
GILD Gilead Sciences, Inc. $207.8B — (loss-making) — (loss-making) +6.83% (above 0%: growing) −20.16% (below 0%: shrinking) +21.13% (above 0%: growing) 81.07% 41.71% Compare
PFE Pfizer Inc. $158.2B 38.8× 18.7× FY26e −0.43% (below 0%: shrinking) −9.68% (below 0%: shrinking) +20.02% (above 0%: growing) 75.71% 22.14% Compare
NVO Novo Nordisk A/S $128.6B 9.8× — +3.87% (above 0%: growing) −17.14% (below 0%: shrinking) −14.75% (below 0%: shrinking) 76.97% 29.06% Compare
BMY Bristol Myers Squibb Company $119.3B 12.9× 12.0× FY26e +6.93% (above 0%: growing) −2.78% (below 0%: shrinking) −35.95% (below 0%: shrinking) 68.28% 19.40% Compare
Median of peers $222.6B 28.8× 24.0× +5.76% −10.87% −14.36% 75.55% 30.48%

All 21 Drug Manufacturers General stocks →

Analyst rating changes each firm’s latest, last six months

Firm Date Action Rating Target Change
Nordea Oct 20, 2026 Upgrade Sell → Buy — —

AstraZeneca PLC (AZN) Latest News

What happened

  1. Product AstraZeneca won US and EU approval for Klygefa, a once-weekly self-administered treatment for adults with generalized myasthenia gravis.
  2. Product AstraZeneca received US approval for perioperative IMFINZI with neoadjuvant enfortumab vedotin for certain adults with muscle-invasive bladder cancer.
  3. Other AstraZeneca cut about 600 US commercial roles as part of a three-year restructuring targeting $1.5 billion in annual pretax savings and up to $2 billion in charges.
  4. Deal AstraZeneca acquired Omniose for an undisclosed sum, adding its bioconjugation platform to the company’s infectious disease unit.
  5. Results AstraZeneca reaffirmed its 2026 earnings guidance and reported third-quarter and nine-month results.
18 more headlines
All AZN news, as stories →

AZN metrics, ten years each

stockrow.com/AZN · Data as of Nov 18, 2026 · For information only; not investment advice. · © 2026 stockrow.com